IF0 trade ideas
IFRX 1D Continuedtest
Just having some fun after a great ski trip to Breckenridge, Co for a couple of weeks. Let's get back into it.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
InflaRx recovering temporarily. IFRXWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
IFRX 1D Swing Editiontest
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
InflaRx Announces Positive Data from Third Cohort of Phase IIa OIFRX: InflaRx N.V.
2021-10-27 07:30:00
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
$IFRX Strong Close!Keeping this one on watch most likely looking for the same volume coming in Monday. We closed very strong on Friday Which typically means we are looking for a strong move to the upside on Monday... Also looking for that SweetSpot break at $2.85 for Entry Confirmation.
$IFRX is gonna fall todayPupm&Dump trading strategy idea.
$IFRX is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $3,21;
stop-loss — $3,35;
take-profit — $2,93/MOC
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
IFRX Technical Analysis 🧙InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
LONG // IFRX // US STOCKSTrade Safe! Don`t be greedy!
Take care and place small trades! If necessary, I will place more long trades at this asset!
In my opinion, this stock is at a good opportunity and has good potential for the stock price to go up!
$IFRX can rise in the next daysContextual immersion trading strategy idea.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $7,22;
stop-loss — $6,73.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
InflaRx Announces Positive Initial Data from Ongoing Phase IIa OIFRX: InflaRx N.V.
2020-02-26 07:30:10
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
Either going up now or after the reboundIFRX has just touched a semi-stable horizontal support and may bounce up or perhaps dip down to the underlying support and then rebound. Keep a close eye on this one.
Long Considerations for $IFRX>Bio of InflaRX<
2008 - Dutch pharma company founded in Germany
2017 - IPO on NASDAQ with gross proceeds of +$100M
2018 - Second round of funding with +$100M
2019 - Balance sheet shows working capital > $150M
>My opinion<
Seems like this company has recently hit a rough patch as far as their scientific studies go, but the financials look rock solid.
I don't think there will be another opportunity in the future to buy in at ~$3. I entered at $3.20 and placed a stop loss at $2.95 for safety.
I think $IFRX could be a potential 10 bagger (10x returns), especially looking at the weekly chart and seeing the share value increased to $30 after IPO in just 14 weeks.
My estimate for value to return to double digits is 2-3 weeks time, since InflaRX released a statement on June 13, 2019 that their first patient is being treated.
These initial trials tend to run multiple months, with weekly reports generated (though they may be published with delay)
I expect InflaRX to publish results as they are produced to help out their shareholders.
>Notes<
Multiple medical studies in the USA and EU.
Estimated # of patients that may benefit from medicine is > 500,000.
Active press releases here > www.inflarx.de
Financials published here > www.inflarx.de
IFRX ready for reversal. Entry point. 8% risk to 25% reward.This is my first share post. Using this as a swing trade analysis.
1. Stock broke the 50 day MA on May 7th, closing at $42.68
2. Stock Reached 20 RSI on May 20th, closing at $38.41 making a 1st Low of $38.18 with 20 RSI.
3. Stock made a 2nd new low on May 22nd of $37.87, closing at $38.05 with RSI reversing upwards to 30 RSI.
4. Market shows sign of reversal on May 23rd, closing at $39.10, 2.76% higher than May 22nd.
5. If stock breaks May 22nd high of $40.68 within the next 5 days, upward reversal should be valid.
6. At this point entry should be about .5% higher than May 22nd high of $40.68, so at $40.88 if reached by May 30th.
7. This reversal will be invalidated if stock makes a new low by May 30th.
8. If this reversal is Valid, stop loss should be anywhere between $35.87-$37.61.
9. With validated reversal and a resistance level of $51.15, this should have a 1 to 3 profit vs risk level, so about 8% risk vs 25% profit.
10. Resistance level should hit within the next 3-4 weeks.
IFRX - Why I like this for a potential swing tradeAfter a blah 2018, trading sideways to downward for most of that year, IFRX had a final, sharp captulation move down in December 2018 and then after the last set of sellers threw in the towel, a sharp rally up. From there...2019, we have been in an uptrend. I like the sharp, drastic moves higher and lower...with higher highs and higher lows. With the most recent peak ending, we had a sharp move down yesterday (4/29/19). In this video, I explain what I like about it and the point where I would like to get in for a swing trade back up if it "behaves". :-)
IFRX - Overbought, looking to come back to uptrend supportWow, this stock has some nice, sharp moves up and down within a nice uptrend that started in 2019. Looks overbought right now, depending on timing...might be a nice swing trade between 43.50 and 41.50. Adding this to my watchlist. Will tweet if/when I enter along with stop loss and profit targets
IFRX BiotechThis company develops anti-inflammatory drugs and is expected to release data soon. I anticipate more growth to mid 60's in the coming months
